Boehringer Ingelheim and DxS Sign Agreement to Identify EGFR Mutations in Patients with Lung Cancer
News Jun 03, 2009
DxS and Boehringer Ingelheim have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992 (Tovok™) to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non small cell lung cancer. Financial terms of the agreement are not disclosed.
Clinical data published to date suggest that BIBW 2992 offers a marked increase in efficacy in comparison to standard treatments, for lung cancer patients carrying mutations in the EGFR gene. Under the terms of the agreement, DxS and Boehringer Ingelheim will work jointly to make a suitable companion diagnostic test kit globally available.
BIBW 2992 is a novel tyrosine kinase inhibitor that acts by irreversibly blocking the EGFR /HER2 receptors, which are promoters of tumor growth. As with other tyrosine kinase inhibitor therapies, patients with mutations in the EGFR gene will be more likely to respond to a medication that targets these receptors, thereby allowing doctors to prescribe the most effective and individual treatment.
Furthermore BIBW 2992 has demonstrated preclinical activity against erlotinib and gefitinib resistant mutations. With this approach, Boehringer Ingelheim is among the few companies advancing molecules of their pipeline within the area of personalized medicine.
The DxS EGFR companion diagnostic is a real-time PCR assay, designed to detect the most common mutations in the EGFR gene. The diagnostic has been developed and manufactured at DxS’ head office in Manchester, UK. and will be available later in the summer for Boehringer Ingelheim’s global, multi-centre Phase III clinical trial for BIBW 2992.
Commenting on this announcement, Dr Stephen Little, CEO of DxS says “This is another great endorsement of our companion diagnostic assays for predicting patient response to targeted therapies. It is an exciting step forward for personalized medicine and DxS is pleased to be at the forefront of this revolution in cancer treatment."
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE